secretagogue


Also found in: Dictionary, Wikipedia.

secretagogue

 [se-krēt´ah-gog]
1. causing a flow of secretion.
2. an agent that so acts.

se·cre·ta·gogue

(se-krē'tă-gog), Avoid the misspelling secretogogue.
An agent that promotes secretion; for example, acetylcholine, gastrin, secretin.
[secreta + G. agōgos, drawing forth]

secretagogue

/se·cret·a·gogue/ (se-krēt´ah-gog) stimulating secretion, or an agent that so acts.

secretagogue

(sĭ-krē′tə-gôg′, -gŏg′)
n.
A hormone or another agent that causes or stimulates secretion.

secretagogue

[sikrē′təgog′]
any agent that induces exocrine, endocrine, or paracrine secretion.

se·cre·ta·gogue

, secretogogue (sĕ-krētă-gog, -tŏ-gog)
An agent that promotes secretion (e.g., acetylcholine, gastrin, secretin).
[secreta + G. agōgos, drawing forth]

se·cre·ta·gogue

, secretogogue (sĕ-krētă-gog, -tŏ-gog)
Agent that promotes secretion.
[secreta + G. agōgos, drawing forth]

secretagogue

1. causing a flow of secretion.
2. an agent that stimulates secretion.
References in periodicals archive ?
Each of the secretagogues use a different pathway of mast cell activation and these pathways may be differentially sensitive to the action of hydroxytyrosol or oleuropein.
Interestingly, thiazolidinedione, an insulin sensitiser protected women against cancer (32 percent lowered risk) than an insulin secretagogue known as sulphonylurea.
Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans.
Furthermore, insulin is a potent secretagogue of leptin that has a close partnership with insulin in control of appetite (Barr et al.
In addition to diet and exercise, oral treatment options have been broadened, with both insulin secretagogues and insulin sensitizers.
32] Patients were advised to increase their fluid and secretagogue intake prior to therapy, and those who could tolerate it were given pilocarpine.
Therefore, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia when used in combination with Onglyza.
Potential insulin secretagogue effects of isovitexin and swertisin isolated from Wilbrandia ebracteata roots in non-diabetic rats.
Ghrelin, an endogenous growth hormone secretagogue with diverse endocrine and nonendocrine effects.
Glufast(R), a rapid onset and short-acting insulin secretagogue, was launched in 2004; Salagen(R), a therapeutic agent for dry mouth induced by radiation therapy for head and neck cancer was introduced in 2005; and Urief(R), used for the treatment of dysuria associated with benign prostatic hyperplasia (BPH), was put on the market in 2006.

Full browser ?